Marker Therapeutics (NASDAQ:MRKR) vs. Valneva (NASDAQ:VALN) Head-To-Head Review

Marker Therapeutics (NASDAQ:MRKR) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Valuation and Earnings

This table compares Marker Therapeutics and Valneva”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	N/A	N/A	-$12.16 million	($0.41)	-2.22
Valneva	$197.56 million	2.77	-$130.33 million	($2.11)	-2.73

Marker Therapeutics has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Marker Therapeutics and Valneva, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1	0	2	1	2.75
Valneva	2	0	1	0	1.67

Marker Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 998.90%. Valneva has a consensus target price of $9.30, indicating a potential upside of 61.49%. Given Marker Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Marker Therapeutics is more favorable than Valneva.

Risk and Volatility

Marker Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.

Profitability

This table compares Marker Therapeutics and Valneva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	N/A	-56.96%	-47.82%
Valneva	-110.33%	-153.20%	-39.50%

Summary

Marker Therapeutics beats Valneva on 11 of the 14 factors compared between the two stocks.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.